Business Wire

WISE

27.1.2023 11:10:38 CET | Business Wire | Press release

Share
Wise Enters 2023 With 15 New Partners in 4 New Markets, Bringing Total to Over 60 Partners Worldwide

Wise, the global technology company building the best way to move money around the world, launched 15 new partnerships in 2022 and enters 2023 with a total of 60 partners globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005068/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Map features select Wise Platform partners only (Photo: Business Wire)

These partnerships are made possible through Wise Platform, which allows banks and businesses to embed the power of Wise into their existing platform. Almost 10 million new customers gained access to Wise, via Wise Platform, in 2022 alone.

What’s more, Wise Platform launched in four new markets last year: in Israel with credit card company Max, in Turkey through Wise’s partnership with Birlesik Odeme and Fibabanka, in the UAE with neobank Wio, and in Hong Kong with virtual bank ZA Bank.

Wise Platform also deepened their footprint in Asia and North America, expanding in two areas in particular: investments and business services. In Singapore, Wise Platform partnered with Tiger Brokers and GoTrade to help make global investing easier for everyone, while in the US, new partners AvidXchange, Ramp, Brex, and Firstbase are providing businesses with key tools to help them operate internationally.

In the UK, Wise launched with Wagestream, a financial wellbeing app for front line workers, and Onfolk, an HR and payroll company, strengthening their impact on how people around the world are paid by their employers.

In addition to new partners, 2022 also saw Wise Platform grow existing partnerships. This included introducing new business services with Monzo and Yapeal, a freelancer service with Multiplier, and a quicker, expanded service with Deel.

Finally, Wise Platform launched International Receive, which makes it easier for banks to efficiently and reliably receive international payments through the Swift network. International Receive gives neobanks an easy route to enabling customers to receive money from abroad, and allows established banks to benefit from Wise Platform’s speed and affordability. The integration can be done in just a matter of weeks.

Steve Naudé, Head of Wise Platform, said:
“Wise Platform’s expansion is a testament to the relevance of our offer to businesses and their customers across multiple industries. We allow our partners to integrate a market-leading cross-border payments infrastructure into their platform quickly and at relatively low cost. This allows them to better serve customers while maintaining a focus on their core business.

“With every partnership we offer more customers and businesses access to fast, cheap, convenient and transparent international payments. We look forward to working with more partners - both new and old - in 2023 as we move ever-closer to our mission of money without borders for everyone.”

Dan Drees, Chief Growth Officer of AvidXchange, said:
“Partnering with Wise to provide our customers with best-in-class international payment capabilities was an easy decision because of their market-leading platform and seamless integration capabilities. Together, we are dedicated to making our customers’ payments process more efficient regardless of country lines.”

Dan Westgarth, Chief Operating Officer at Deel, said:
“Wise’s new feature allows even more Deel customers to use their local currency and local payment system, expanding our capabilities and bringing the Wise experience to more businesses around the world. This is massively beneficial for our customers, who choose Deel to make hiring, onboarding, and executing payroll for overseas employees a breeze.”

About Wise Platform
Over the past decade, Wise (formerly known as Transferwise) has built a global payments infrastructure that has revolutionised how money moves around the world. Wise Platform is Wise - but for banks, large businesses and other major enterprises. Wise Platform allows other companies to leverage the power of Wise and embed the best way to send, receive, and manage money internationally into their existing infrastructure.

Wise Platform saves partners time and money by allowing them to deploy new products and services to customers seamlessly, helping them to speed up innovation and serve, retain, and grow their customer base.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005068/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye